Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners. Watch the video here.

Less Ads, More Data, More Tools Register for FREE
Tribe Technology set to deliver healthy pipeline of orders from Tier-One miners
Tribe Technology set to deliver healthy pipeline of orders from Tier-One minersView Video
Andrada Mining acquisition elevates the miner to emerging mid-tier status
Andrada Mining acquisition elevates the miner to emerging mid-tier statusView Video

Latest Share Chat

Pin to quick picksSanofi Share News (SAN.PA)

Share Price Information for Sanofi (SAN.PA)

Euronext Paris
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 89.94
Bid: 93.35
Ask: 93.36
Change: 0.08 (0.089%)
Spread: 0.01 (0.011%)
Open: 90.23
High: 90.59
Low: 89.73
Prev. Close: 89.86
SAN.PA Live PriceLast checked at -
  • This share is an international stock.

Watchlists are a member only feature

Login to your account

European shares tick higher; Aegon shines on forecast raise

Thu, 11th Aug 2022 17:29

Aug 11 (Reuters) - European shares edged higher on Thursday after a strong rally in the previous session on signs of U.S. inflation cooling, while Aegon climbed after the Dutch insurer raised its full-year forecast.

The pan-European STOXX 600 index rose 0.1%, after clocking its best session in nearly two weeks on Wednesday on bets that a softer-than-expected U.S. inflation reading would encourage the Federal Reserve to become less aggressive on interest rates hikes.

"Even if European stocks are not rallying as some of their counterparts today, they're going up as the interpretation by markets is that the inflation numbers were synonymous with the Fed changing its policy," said Sebastian Paris-Horvitz, head of research at La Banque Postale Asset Management.

Money markets are pricing in over a 60% chance of a 50 bps hike from the Fed at next month's meeting.

Oil stocks led gains as crude prices rose by over 1% after the International Energy Agency raised its oil demand growth forecast for the year.

Healthcare shares led losses, dragged by declines in GSK, Sanofi and Haleon amid growing concerns about U.S. litigation focused on a heartburn drug that contained a probable carcinogen.

Miners also fell 0.8% on weak results from Antofagasta. The company's shares declined 2.2% and dragged peer Rio Tinto down 3.7%.

The STOXX 600 is down about 10% so far this year, compared with a more than 11% decline for Wall Street's S&P 500 index . U.S. equities are heavily dependent on moves in big technology stocks, which fell sharply in the first half of the year on worries over rising interest rates.

"The big decline in global markets in the first quarter was associated with big growth stocks in the U.S. falling, and therefore Europe, which is less heavy on those, outperformed," Paris-Horvitz added.

Still, Europe is struggling with the fallout of the war in Ukraine as it looks to source energy from non-Russian sources.

Germany, often referred to as the European Union's economic engine, is also struggling with scant rainfall. Low water levels on the Rhine, Germany's commercial artery, have disrupted shipping and pushed freight costs up more than five-fold.

Among stocks, Aegon jumped 8.9% after raising forecasts for full-year operating capital generation and 2021-2023 free cash flow. Zurich Insurance Group added 1.7% as it reported a better-than-expected profit gain in the first half.

Siemens gained 0.7%. The engineering group said it continued to see strong industrial demand during its third quarter, but a writedown at Siemens Energy resulted in its first quarterly loss in nearly 12 years.

(Reporting by Shreyashi Sanyal, Anisha Sircar and Johann M Cherian in Bengaluru; Editing by Sriraj Kalluvila and Mike Harrison)

More News
24 Feb 2023 15:10

First Zantac cancer risk trial in Calif. postponed five months

Feb 23 (Reuters) - The first scheduled trial over claims that GSK Plc's heartburn drug Zantac caused cancer, which had been set to begin Monday, has been postponed by five months.

Read more
16 Feb 2023 23:17

Judge weighs key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - Lawyers for a man who alleges he developed bladder cancer after taking GSK Plc's heartburn drug Zantac urged a California judge on Thursday to allow expert testimony linking the drug to the illness at an upcoming trial.

Read more
16 Feb 2023 19:38

Judge to weigh key evidence ahead of first Zantac cancer trial

Feb 16 (Reuters) - GSK Plc is expected to urge a California judge on Thursday to limit what expert testimony jurors can hear in the first trial over claims that the company's heartburn drug Zantac caused cancer.

Read more
13 Feb 2023 17:19

European shares rise as defence stocks rally, focus on U.S. inflation data

STOXX 600 ends up 0.9%

*

Read more
3 Feb 2023 17:27

European shares log weekly gains, UK's blue-chip index hits record high

STOXX 600 up 0.3%, logs gains for second straight week

*

Read more
3 Feb 2023 11:49

Sanofi forecasts moderate profit growth on Dupixent demand

Sees "low single digit" percentage core EPS growth, FX adjusted

*

Read more
31 Jan 2023 12:26

Share buybacks in Europe as significant as in U.S.

STOXX 600 down around 1%

*

Read more
31 Jan 2023 11:30

Banks: six reasons to be overweight

STOXX 600 down 1%

*

Read more
31 Jan 2023 09:15

STOXX slides

STOXX 600 down 0.5%

*

Read more
31 Jan 2023 07:36

European shares seen lower

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

EUROPEAN SHARES SEEN LOWER (0730 GMT)

Read more
31 Jan 2023 06:56

Mind the gap

Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at

MIND THE GAP (0656 GMT)

Read more
30 Jan 2023 20:27

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
30 Jan 2023 17:42

Drugmakers prevail in dispute over U.S. discount drug program

Jan 30 (Reuters) - Drug manufacturers can limit healthcare providers' use of outside pharmacies for dispensing drugs under a federal drug discount program, a federal appeals court ruled Monday.

Read more
4 Jan 2023 10:51

Sanofi sees decision on Zantac dispute with Boehringer in Q1 at earliest

Arbitration decision initially expected by end of 2022

*

Read more
12 Dec 2022 21:46

Amgen dives deeper into rare disease drugs with $27.8 bln Horizon deal

Dec 12 (Reuters) - Amgen Inc on Monday agreed to buy Horizon Therapeutics Plc in a deal valued at $27.8 billion, fortifying its rare diseases portfolio in the biggest buyout in the sector this year.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.